Adaptimmune Therapeutics

Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Adaptimmune reports strong Q1 results, eyes market leadership with afami-cel

Adaptimmune Therapeutics shows strong performance and progress in Q1 2024.
Strengths lie in innovative therapies, financial stability, and clear development plans.
Challenges include managing debt impact, FDA processes, and successful product launches.
Opportunities exist in market leadership, upcoming presentations, and growth strategies.

Adaptimmune achieves commercial milestone with Tecelra launch, poised for growth

Adaptimmune's Q2 performance reflects a transformative phase as it transitions into a commercial-stage company with a strong financial position and a focus on innovative cell therapies.
While facing challenges in operational execution and revenue forecasting, the company's strategic strengths lie in its pioneering treatments, robust pipeline, and customer-centric approach.
By capitalizing on opportunities for market expansion, strategic partnerships, and operational optimization, Adaptimmune is poised to drive growth and establish itself as a key player in the cell therapy sector.

Adaptimmune targets breakeven by 2027 with strong sarcoma franchise

Adaptimmune Therapeutics is strategically positioned to achieve operating breakeven by 2027 through significant cost reductions and a focus on their sarcoma franchise with Tecelra and lete-cel.
The company's financial stability, positive trial results, and revenue targets indicate a strong growth trajectory and confidence in their business strategy.
While facing challenges in cost reduction and workforce restructuring, Adaptimmune Therapeutics has opportunities to capitalize on market expansion and product efficacy to drive future growth.
Overall, the company's performance in Q3 reflects a proactive approach to financial sustainability and market competitiveness in the oncology sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Adaptimmune Therapeutics Plc is commercial-stage cell therapy company, which focuses on providing novel cell therapies to people with cancer. Its clinical pipeline includes Afami-cel, Lete-cel, and ADP-A2M4CD8. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.

- SPEARHEAD-1 met its primary endpoint - planning for afami-cel BLA submission in Q4 2022 for people with synovial sarcoma -

Adaptimmune Reports Fourth Quarter and Full Year 2021 Financial Results and Business Update

PHILADELPHIA and OXFORDSHIRE, United Kingdom, March 08, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide business updates for the fourth quarter and year ended December 31, 2021, before the US markets open on Monday, March 14, 2022. Following the announcement, the Company will host a live teleconference and webcast at 8:30 a.m. EDT (12:30 p.m. GMT) that same day (details below).

Adaptimmune to Report Q4 and Full Year 2021 Financial Results and Business Updates on Monday, March 14, 2022

I must say up front that I do not expect ADAP to make me a profit in the next 12 months because of the poor market conditions.

Adaptimmune Therapeutics: A Little More Patience May Be Profitable

The heavy selling pressure might have exhausted for Adaptimmune Therapeutics PLC (ADAP) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

After Plunging 19.1% in 4 Weeks, Here's Why the Trend Might Reverse for Adaptimmune Therapeutics PLC (ADAP)

PHILADELPHIA and OXFORDSHIRE, United Kingdom, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announces the appointment of Cintia Piccina as Chief Commercial Officer effective January 31, 2022.

Adaptimmune Announces Appointment of Cintia Piccina as Chief Commercial Officer

Clovis Oncology

The biotech bear market has punished these two stocks too severely at this point.

2 Cancer Stocks With Absurdly Low Valuations

Alnylam Pharmaceuticals

Biogen

BioMarin Pharmaceutical

CRISPR Therapeutics

We discuss a few companies like BioMarin (BMRN), Adaptimmune (ADAP), CRISPR Therapeutics (CRSP), and Alnylam Pharmaceuticals (ALNY) with solid product portfolios, deep pipelines which make them attractive candidates for a potential takeover in 2022.

4 Biotechs That Could Be Potential Takeover Targets in 2022

Affimed

Aurinia Pharmaceuticals

Axsome Therapeutics

BridgeBio Pharma Inc

BioCryst Pharmaceuticals

Beam Therapeutics

Amicus Therapeutics

SPDR S&P Biotech ETF

These eight stocks could rebound nicely over the next year and beyond.

8 Beaten-Down Pharmaceutical Stocks That Could Skyrocket In 2022

Agenus

Ocugen, Inc.

A mix of marketwide headwinds and company-specific events weighed on these three biotech stocks in November.

Here's Why Biotech Stocks Adaptimmune Therapeutics, Agenus, and Ocugen All Crashed in November

Investor sentiment has turned against this promising cell therapy company.

Why Adaptimmune Therapeutics Stock Is Crashing Today

Adaptimmune Therapeutics and Agenus are having a tough go of it in the final quarter of 2021.

2 Falling-Knife Stocks Actually Worth Buying Right Now

- Inhibition of AKT signaling during ex vivo T-cell expansion phase of manufacturing provides further proliferative potential and enhanced memory phenotype of next-gen SPEAR T-cells -

Translational Data at SITC 2021 from Adaptimmune's Phase 1 SURPASS Trial Indicate Adding AKTi to Manufacturing May Contribute to Sustained Antitumor Activity of Next-gen SPEAR T-cells

Adaptimmune Therapeutics plc (NASDAQ: ADAP) will report updated data from its SPEARHEAD-1 Phase 2 trial with afamitresgene autoleucel (afami-cel, ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma (MRCLS) at the Connective Tissue Oncology Society annual meeting. The Company says that the trial will meet its primary endpoint for efficacy, and the data will be used to support marketing application filing for afami-cel next year.

Adaptimmune Bullish On Meeting Endpoint For Soft Tissue Cancer Trial

- SPEARHEAD-1 trial will meet its primary endpoint and data will be used to support BLA filing for afami-cel next year -

Adaptimmune Reports Positive Results from its Pivotal SPEARHEAD-1 Trial in Patients with Synovial Sarcoma and MRCLS at CTOS

Adaptimmune Therapeutics plc (ADAP) CEO Adrian Rawcliffe on Q3 2021 Results - Earnings Call Transcript

Pfizer

These two small-cap cancer companies would be a perfect fit for Pfizer.

2 Biotech Companies That Might Be on Pfizer's Radar Right Now

Adaptimmune Therapeutics (NASDAQ:ADAP) reported its Q3 earnings results on Thursday, November 4, 2021 at 08:00 AM. Here's what investors need to know about the announcement.

Adaptimmune Therapeutics: Q3 Earnings Insights

PHILADELPHIA and OXFORDSHIRE, United Kingdom, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide a business update for the third quarter ended September 30, 2021, before the US markets open on Thursday, November 4, 2021. Following the announcement, the Company will host a live teleconference and webcast at 8:00 a.m. EDT (12:00 p.m. GMT) that same day (details below).

Adaptimmune to Report Q3 2021 Financial Results and Business Update on Thursday, November 4, 2021

These two novel-drug makers could be top takeover targets next year.

2 Top Healthcare Stocks That Could Be Bought Out in 2022

- Clinical update and translational data from SPEARHEAD-1 in patients with synovial sarcoma and MRCLS to be presented at CTOS -

Adaptimmune to Present Data Updates at Upcoming CTOS and SITC Meetings

Adaptimmune Therapeutics has a diverse pipeline focused on TCR-engineered T cells. Their most advanced candidate, afamitresgene autoleucel, will likely receive approval.

Adaptimmune Therapeutics: Diverse Pipeline With Approval Looming

Corvus Pharmaceuticals

Verastem

These three low-priced cancer stocks could be grossly undervalued.

3 Biotech Stocks That Could Make You Filthy Rich

Adaptimmune (ADAP) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

Can Adaptimmune (ADAP) Run Higher on Strong Earnings Estimate Revisions?

Profit-taking seemed to be the general dynamic behind the biotech's 14% slide.

Why Adaptimmune Therapeutics Was Sinking This Week

Adaptimmune Therapeutics plc (NASDAQ: ADAP) has announced updated data from its Phase 1 SURPASS trial in multiple solid tumors evaluating ADP-A2M4CD8. ADP-A2M4CD8 is a next-generation T-cell therapy engineered to target MAGE-A4 positive tumors and to express a CD8α co-receptor.

News for Adaptimmune Therapeutics Stock (ADAP)